EUVIMEDEUVIMED entdecken
VergleichsstudieKlinische StudieOpen Access · CC BY-NC-ND 4.0

The efficacy and safety of ZR2 versus R-CHOP-like for elderly patients with newly diagnosed diffuse large B cell lymphoma: a single-center prospective study in China

Panruo Jiang, Rongqi Li, Hui Li, Yilan Xu, Zhenyan Xu, Chongyun Xing, Kang Yu, Songfu Jiang, Xiuhua Zhang, Haige Ye

Annals of Hematology · 2024

DOI: 10.1007/s00277-024-06066-3 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Annals of Hematology, 2024. Verfasst von Panruo Jiang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Dongyang People's Hospital, Jinhua, Zhejiang, China. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Antineoplastic Combined Chemotherapy Protocols, Pyrazoles. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Natural Science Foundation of Zhejiang Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bruton's tyrosine kinase inhibitors have been demonstrated preliminary efficacy in diffuse large B-cell lymphoma (DLBCL). To compare the safety and efficacy of zanubrutinib plus rituximab and lenalidomide (ZR2) and R-CHOP-like for elderly patients with newly diagnosed DLBCL, we conducted this single-center prospective study. Patients were treated with 6 cycles of ZR2 or R-CHOP-like regimen for the first-line treatment. The primary endpoint was complete response ratio (CRR). The secondary outcome measures were progression-free survival (PFS), overall survival (OS), and adverse events. Between June 15, 2020, and March 11, 2023, 30 patients with ZR2 and 60 patients with R-CHOP-like were enrolled. There were no significant differences observed in CRR (P = 0.878), PFS (P = 0.555) and OS (P = 0.769) between ZR2 and R-CHOP-like group. While, patients in ZR2 group had the following features: significantly older (P = 0.002), more unfit (P < 0.001) and higher prognosis risk scores (P = 0.025). The incidence of grade ≥ 3 anemia (P = 0.008) and pneumonia (P = 0.001) was significantly lower in ZR2 group. Patients with germinal center B-cell-like subtype (GCB), large masses or TP53 mutations had a satisfactory remission rate in ZR2 group (57.1%, 77.8% and 60.0%, respectively). ZR2 and R-CHOP-like regimen had similar efficacy and survival. While, the safety profile for ZR2 was superior. GCB subtype, large masses and TP53 mutations may benefit from ZR2 regimen as well. Patients with EBV-positive and CARD11 mutations may need additional treatment rather than ZR2. Patients with gastrointestinal DLBCL have to be monitored closely by abdominal enhanced CT every cycle. Overall, ZR2 chemo-free regimen might be more appropriate for elderly DLBCL patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Large B-Cell, DiffuseAntineoplastic Combined Chemotherapy ProtocolsPyrazolesHumansAgedMaleFemaleRituximabVincristineCyclophosphamidePrednisoneDoxorubicinProspective StudiesChinaAged, 80 and overMiddle AgedTreatment Outcome

Stichwörter der Autor:innen

Elderly patientLenalidomideNewly diagnosed diffuse large B-cell lymphomaZanubrutinib

Substanzen

RituximabVincristineCyclophosphamidePrednisoneDoxorubicinR-CHOP protocolPyrazoles

Autor:innen und Institutionen

  • Department of Hematology, Dongyang People's Hospital, Jinhua, Zhejiang, China.
  • Department of Pharmacy, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
  • Department of Hematology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
  • Department of Hematology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China. jsongfu@163.com.
  • Department of Pharmacy, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China. Wzzhangxiuhua@126.com.
  • Department of Hematology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China. haigeye@wzhospital.cn.

Förderung

  • Natural Science Foundation of Zhejiang Province

Zitieren

APA

Jiang, P., Li, R., Li, H., Xu, Y., Xu, Z., Xing, C., Yu, K., Jiang, S., Zhang, X., & Ye, H. (2024). The efficacy and safety of ZR2 versus R-CHOP-like for elderly patients with newly diagnosed diffuse large B cell lymphoma: a single-center prospective study in China. Annals of Hematology. https://doi.org/10.1007/s00277-024-06066-3

Vancouver

Jiang P, Li R, Li H, Xu Y, Xu Z, Xing C, et al. The efficacy and safety of ZR2 versus R-CHOP-like for elderly patients with newly diagnosed diffuse large B cell lymphoma: a single-center prospective study in China. Annals of Hematology. 2024. doi:10.1007/s00277-024-06066-3

BibTeX
@article{Jiang2024,
  author = {Jiang, Panruo and Li, Rongqi and Li, Hui and Xu, Yilan and Xu, Zhenyan and Xing, Chongyun and Yu, Kang and Jiang, Songfu and Zhang, Xiuhua and Ye, Haige},
  title = {The efficacy and safety of ZR2 versus R-CHOP-like for elderly patients with newly diagnosed diffuse large B cell lymphoma: a single-center prospective study in China},
  journal = {Annals of Hematology},
  year = {2024},
  doi = {10.1007/s00277-024-06066-3}
}
Kostenlos starten →